Sulpiride Belupo, 200 mg capsules 12 pcs

ATX:
N.05.A.L Benzamides

Pharmacodynamics:

Sulpiride is an atypical neuroleptic from the group of substituted benzamides and has moderate neuroleptic activity combined with stimulant and thymoanaleptic (antidepressant) effects. The neuroleptic effect is associated with antidopaminergic action. In the central nervous system (CNS), sulpiride blocks predominantly dopaminergic receptors of the limbic system, the effect on the neostriatal system is insignificant.

Indications

As monotherapy or in combination with other psychotropic drugs.

Active ingredient

How to take, the dosage

Interaction

The simultaneous use of sulpiride and CNS depressant drugs (narcotic analgesics, antihistamines, barbiturates, benzodiazepines and other anxiolytics) may increase the sedative effect of these drugs.

The combination of sulpiride with alcohol may also increase the sedative effect of alcohol.

Combination with levodopa should be avoided because of the mutual antagonism of levodopa and sulpiride.
There is an increased risk of orthostatic hypotension when sulpiride and antihypertensive agents are taken concomitantly.
Sucralfate, antacids containing Mg2+and/or Al3+ reduce bioavailability by 20-40%.

Antagonism with dopaminergic receptor agonists (amantadine, apomorphine, bromocriptine, cabergoline, entacapone, lisuride, pergolide, pyribedil, pramipexole, quinagolide, ropinirole) and neuroleptics. In extrapyramidal syndrome induced by neuroleptics, dopaminergic receptor agonists are not used but anticholinergic medications are. If it is necessary to treat patients with Parkinson’s disease against the background of using dopaminergic receptor agonists, the dose of the latter should be gradually reduced until complete withdrawal (abrupt withdrawal may lead to the development of malignant neuroleptic syndrome).

The risk of ventricular arrhythmias such as “torsade de pointes” when used simultaneously with: Class 1a (quinidine, hydroquinidine, disopyramide) and Class III (amiodarone, sotalol, dofetil, ibutilide) antiarrhythmic drugs, some neuroleptics (thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, amisulpride, thiapride, haloperidol, droperidol, pimozide), bradycardia-inducing drugs (diltiazem, verapamil, beta-blockers, clonidine, guanfacine foxglove drugs, donepizil, rivastigmine, tacrine, ambenonium chloride, galantamine, pyridostigmine, neostigmine), drugs causing hypokalemia (potassium withdrawing diuretics, some laxatives, Amphotericin B w/v, GCS, tetracosactide) and others (including bepridil, cisapride, difemanil, erythromycin intravenously, misolastin, vincamine w/v, halofantrine, pentamidine, sparfloxacin, moxifloxacin).

Special Instructions

If hyperemia occurs during treatment with Sulpiride Belupo should be discontinued. Hyperemia may be a sign of malignant neuroleptic syndrome (manifested by hyperthermia, dyskinesia, autonomic disturbances) described during treatment with neuroleptics. Although there are no data on the development of the syndrome during treatment with Sulpiride Belupo, caution is necessary, especially when prescribing high doses of the drug.

When Sulpiride Belupo is indicated for patients with epilepsy, a prior clinical and electrophysiologic evaluation must be performed before starting treatment, because the drug reduces the seizure threshold.

Influence on driving and operating machinery

During treatment, driving and operating machinery requiring increased attention as well as alcohol intake are prohibited.

Contraindications

Side effects

Overdose

Symptoms (common to both dosage forms): dyskinesias (spasm of masticatory muscles, spastic torticollis), extrapyramidal disorders. In some cases – pronounced parkinsonism, coma.

When using the tablets, there may be:blurred vision, arterial hypertension, sedation, nausea, dry mouth, vomiting, increased sweating and gynecomastia, development of MNS.

Treatment: symptomatic. Prescription of cholinoblockers of central action.

Pregnancy use

Similarities